Sirtris' review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery

Sirtris, a GSK company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it published a new review article on the growing body of sirtuin research and its potential to treat diseases of aging such as Type 2 Diabetes, mitochondrial disorders, inflammation, cancer, and heart disease. Entitled "SIRTUINS – Novel Therapeutic Targets to Treat Age-Associated Diseases," the review appears in today's issue of the journal Nature Reviews Drug Discovery.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news142068901.html">Sirtris' review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery</a></p> <p>Sirtris, a GSK company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it published a new review article on the growing body of sirtuin research and its potential to treat diseases of aging such as Type 2 Diabetes, mitochondrial disorders, inflammation, cancer, and heart disease. Entitled "SIRTUINS – Novel Therapeutic Targets to Treat Age-Associated Diseases," the review appears in today's issue of the journal <I>Nature Reviews Drug Discovery</I>.</p>